Table 3 Multivariate Cox regression model for exploring the association between FT and clinical outcomes in patients with PD
Model 1 | Model 2 | |||
|---|---|---|---|---|
HR (95%CI) | P-value | HR (95%CI) | P-value | |
Presence of FT at baseline | ||||
Time to death | 1.65 (0.87–3.12) | 0.122 | 1.50 (0.78–2.90) | 0.230 |
Time to UPDRS-III 11-point increase | 1.23 (0.75–2.01) | 0.421 | 1.21 (0.73–2.00) | 0.460 |
Time to conversion to H&Y stage ≥3 | 0.95 (0.52–1.74) | 0.876 | 0.93 (0.51–1.72) | 0.822 |
Time to dyskinesia | 0.64 (0.25–1.61) | 0.340 | 0.57 (0.23–1.45) | 0.241 |
Time to MoCA 3-point decrease | 0.97 (0.57–1.64) | 0.903 | 0.97 (0.57–1.65) | 0.907 |
FT as initial symptom | ||||
Time to death | 2.46 (0.90–6.76) | 0.080 | 2.56 (0.91–7.23) | 0.075 |
Time to UPDRS-III 11-point increase | 0.91 (0.33–2.52) | 0.861 | 0.86 (0.31–2.42) | 0.777 |
Time to conversion to H&Y stage ≥3 | 0.47 (0.11–1.96) | 0.300 | 0.49 (0.12–2.06) | 0.332 |
Time to dyskinesia | 1.07 (0.25–4.47) | 0.931 | 1.09 (0.26–4.63) | 0.906 |
Time to MoCA 3-point decrease | 0.54 (0.17–1.74) | 0.301 | 0.50 (1.16–1.63) | 0.253 |